Sermorelin and Growth Hormone Research: What Practices Need to Know

Sermorelin (GHRH 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that stimulates the pituitary gland to release growth hormone (GH). It has been studied for its effects on GH secretion, body composition, and aging-related changes in GH/IGF-1 axis function.

This post covers the current research landscape for sermorelin as an RUO peptide.

Important reminder: Sermorelin is available from MedClinic Partners as a Research Use Only compound. It is not FDA-approved for therapeutic use and cannot be administered to humans outside of an IRB-approved research protocol.

Growth hormone (GH) is secreted by the pituitary gland in a pulsatile pattern, primarily during sleep. GH stimulates the liver to produce IGF-1 (insulin-like growth factor 1), which mediates many of GH's anabolic effects.

GH and IGF-1 levels decline with age — a phenomenon called somatopause. This decline is associated with:

• Increased body fat (particularly visceral fat)
• Decreased lean muscle mass
• Reduced bone density
• Decreased exercise capacity
• Changes in skin quality
• Altered sleep patterns

The decline in GH/IGF-1 with age has led to interest in interventions that restore or support GH secretion.

Sermorelin is the first 29 amino acids of GHRH (the full molecule has 44 amino acids). This truncated version retains full biological activity at the GHRH receptor.

Unlike exogenous GH administration, sermorelin works by stimulating the pituitary to produce and release GH through the normal physiological pathway. This means:

• GH release remains pulsatile (more physiological)
• The pituitary's feedback mechanisms remain intact
• The risk of supraphysiological GH levels is lower than with direct GH administration

Sermorelin was FDA-approved as a diagnostic agent for GH deficiency in children (Geref) and as a treatment for GH deficiency in children (Geref Diagnostic). This approval was withdrawn in 2008 for commercial reasons, not safety concerns.

The clinical research conducted during the approval process established that sermorelin:

• Stimulates GH secretion in a dose-dependent manner
• Is well-tolerated with a favorable safety profile
• Produces increases in IGF-1 levels

Research has examined sermorelin's effects on body composition in adults with age-related GH decline:

2001 study in Journal of Clinical Endocrinology & Metabolism: Examined sermorelin in older adults with low IGF-1 levels. Sermorelin treatment increased IGF-1 levels and improved body composition (reduced fat mass, increased lean mass) compared to placebo.

Subsequent research: Multiple studies have examined GHRH analogs (including sermorelin and tesamorelin) for body composition effects. The consistent finding is that GHRH analogs increase GH and IGF-1 levels and improve body composition, particularly in patients with documented GH deficiency or age-related GH decline.

Tesamorelin (Egrifta) is a GHRH analog that is FDA-approved for the treatment of HIV-associated lipodystrophy. The tesamorelin research provides important context for understanding GHRH analogs generally:

• Tesamorelin significantly reduces visceral fat in HIV patients with lipodystrophy
• Effects are maintained with continued treatment
• Weight regain occurs after discontinuation (similar to GLP-1 therapy)

The tesamorelin data supports the biological plausibility of GHRH analogs for body composition effects.

CJC-1295 is another GHRH analog that is commonly used in research. The key difference:

Sermorelin (GHRH 1-29): Short half-life (~10-20 minutes). Produces a more physiological pulsatile GH release pattern.

CJC-1295: Modified GHRH analog with extended half-life (days to weeks due to albumin binding). Produces more sustained GH elevation.

The choice between sermorelin and CJC-1295 for research purposes depends on the research question — pulsatile vs. sustained GH elevation.

We supply sermorelin as an RUO peptide with ≥99% purity, COA from independent laboratory, and proper RUO labeling. Available as lyophilized powder.

Contact us about RUO peptide availability →

Sermorelin is a Research Use Only compound. It is not FDA-approved for therapeutic use and cannot be administered to humans outside of an IRB-approved research protocol. For licensed research facilities only.